Company profile
BIOFRONTERA INC.
NASDAQ:BFRIBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AMELUZ | approved | $150.0MQ1 2025 | 0 | — |
| AKTIPAK | approved | — | 6 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02799030 | phase2 | completed | 2006-10-01 | 2007-03-01 | Biofrontera Bioscience GmbH | A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Keratosis |
| NCT02799082 | phase3 | completed | 2007-12-01 | 2008-10-01 | Biofrontera Bioscience GmbH | Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis. |
| NCT02799069 | phase3 | completed | 2008-04-01 | 2009-08-01 | Biofrontera Bioscience GmbH | Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy |
| NCT01966120 | phase3 | completed | 2013-10-01 | 2014-09-01 | Biofrontera Bioscience GmbH | Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT) |
| NCT02144077 | phase3 | completed | 2014-01-28 | 2015-11-17 | Biofrontera Bioscience GmbH | Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy |
FDA applications (2)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 208081 | 2016-05-10 | NDA | BIOFRONTERA INC | |||||
Loading… | ||||||||
| NDA 050769 | 2000-11-27 | NDA | BIOFRONTERA INC | |||||
Loading… | ||||||||